Kwality Pharmaceuticals Limited (NSE:KPL)

Market Cap	40.02B +348.8%
Revenue (ttm)	5.54B +37.9%
Net Income	810.45M +86.7%
EPS	78.10 +86.8%
Shares Out	n/a
PE Ratio	49.38
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,118
Open	3,700.00
Previous Close	3,686.00
Day's Range	3,581.00 - 3,887.20
52-Week Range	1,561.00 - 3,949.00
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Kwality Pharmaceuticals

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides int...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1983
• Employees: 1,137
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KPL

Financial Performance

In fiscal year 2026, Kwality Pharmaceuticals's revenue was 5.03 billion, an increase of 35.90% compared to the previous year's 3.70 billion. Earnings were 673.46 million, an increase of 69.02%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 11, 2026

Data Sources Report a data error